Navigation Links
Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases
Date:7/7/2009

with Zometa.

About Denosumab and Amgen's Research in Bone Biology

Denosumab is the first fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand, the essential regulator of osteoclasts (the cells that break down bone). With more than 19,000 patients in trials across indications worldwide, the denosumab development program is the largest ever initiated by Amgen. This broad and deep development program demonstrates Amgen's commitment to researching and delivering pioneering medicines to patients with unmet medical needs. Amgen is studying denosumab in numerous tumor types across the spectrum of cancer induced bone disease. Over 11,000 patients have been enrolled in the denosumab oncology clinical trials testing the drug for bone loss and destruction associated with cancer treatment-induced bone loss in breast and prostate cancers, for the prevention of skeletal related events due to the spread of cancer to the bone in multiple myeloma and multiple solid tumors, and for its potential to delay bone metastases in prostate cancer.

Bone Metastases: Impact and Prevalence

Bone metastases, cancer cells that separate from tumors and migrate to bone tissue where they settle and grow, occur in more than 1.5 million people worldwide.(1) With improvements in cancer care, including earlier diagnosis and new treatment options, leading to increases in survival rates(2), the number of patients developing metastatic disease secondary to a primary cancer is increasing. Bone metastases are a significant problem for patients with certain types of advanced cancer, with incidence rates of nearly 100 percent in myeloma patients and as high as 75 percent in breast and prostate cancer patients.

With bone metastases the growing cancer cells weaken and destroy the bone around the tumor. The damage the tumor has caused to the bone can result in a number of serious
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis
2. Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
3. Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
4. Study Demonstrates Efficacy of Pitavastatin in Elderly Patients
5. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
6. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
7. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
10. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
11. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014  4WEB Medical announces the ... foot and ankle osteotomy implants on the market ... Society annual meeting in Chicago . ... of a surgeon,s osteotomy needs with 74 size options included ... had smaller offerings of only 15 to 18 implant sizes, ...
(Date:9/19/2014)... NORWALK, Conn. , Sept. 19, 2014 ... , a leading online community to help oncologists ... newest information available regarding the use of targeted therapies ... blood cancer research and treatment.  Every ... as a way to raise awareness about blood cancers—helping ...
(Date:9/19/2014)... 19, 2014  Pressure BioSciences, Inc. (OTCQB: PBIO) ... received and approved all parts required to build ... begun to manufacture the new PCT-based instrument system.  ... ready for shipment by mid-October and that additional ... a rate of about one per week thereafter.  ...
Breaking Medicine Technology:4WEB Medical Unveils 3D-Printed Osteotomy Truss System 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3
(Date:9/19/2014)... led by Medical College of Wisconsin (MCW) scientists has identified ... in rats, mice and in humans. The findings are published ... , Leah Solberg Woods, Ph.D., associate professor of pediatrics ... Wisconsin Research Institute, led the study and is the corresponding ... identified a gene called Tpcn2 in which a variant was ...
(Date:9/19/2014)... Top10BestSEOHosting.com today compares many professional Windows web ... Bluehost are the best suppliers of 2014. Clients ... (including VPS and cloud hosting) at affordable rates ... , HostMonster ( http://www.hostmonster.com/track/seohosts ) helps business companies ... of the cost. As a top rated hosting ...
(Date:9/19/2014)... cancer do not receive any palliative care, reveals new ... ESMO 2014 Congress in Madrid, Spain, 26-30 September. The ... time as 15 new oncology centres in Europe, Canada, ... title of ,ESMO Designated Centre of Integrated Oncology and ... oncology consultant at the Institute of Oncology Bucharest, Romania, ...
(Date:9/19/2014)... San Jose, California (PRWEB) September 19, 2014 ... – Immunoassays are ligand assays used for detection ... antibodies in a given sample. Driven by steady ... overall healthcare industry, the global immunoassay systems market ... incidence of debilitating conditions, such as diabetes, cardio-vascular ...
(Date:9/19/2014)... TN (PRWEB) September 19, 2014 ... has been named a finalist for the 2014 ... founder and president Tammy Hawes has been selected ... the Year. The Nashville Area Chamber of Commerce ... these awards to recognize the accomplishments of companies ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com: They Are Best Windows Web Hosting Suppliers Of 2014 2Health News:Patients with advanced, incurable cancer denied palliative care 2Health News:Patients with advanced, incurable cancer denied palliative care 3Health News:Patients with advanced, incurable cancer denied palliative care 4Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 4Health News:Virsys12 and Founder Tammy Hawes Each Named 2014 NEXT Awards Finalists 2Health News:Virsys12 and Founder Tammy Hawes Each Named 2014 NEXT Awards Finalists 3
... for about 10% to 20 % of women menopausal period ... sweats, hot// flashes (sensation of heat which comes on all ... Therapy (HRT) is the conventional treatment of choice that is ... period. Hormone therapy offers great relief from hot flashes and ...
... Telemedicine, the amalgamation of medicine and modern communications technology, ... monitor patients at a distance means they// can leave ... doctor, which also saves money. ,Christian Weigand, ... Circuits in Erlangen, Germany, said telemedicine could help people ...
... olive oil, glycerine and egg yolk would prevent ... ,The journal of Catheterization and Cardiovascular Interventions ... by Michael Savage, M.D., director, Cardiac Catheterization Laboratory ... mixture is not swallowed, Dr. Savage explains. Rather, ...
... the aging brain produces progressively fewer new nerve ... scientists said the finding, made in rodents, refutes ... cells persist in the aging brain. ... various neurodegenerative disorders, including Alzheimer's disease, dementia and ...
... diabetes and heart disease, lifestyle changes are making a ... study suggests that by reducing the intake beverages saturated ... their risk of developing cardiac diseases in the future. ... hypertension and type-2 diabetes has largely dealt with adults," ...
... signal an oncoming cold, many people reach for what ... tea or capsule containing //echinacea. In the first study ... bacteria in the gastrointestinal tract, research at the University ... side effects with this common herbal remedy. ,Although ...
Cached Medicine News:Health News:Natural Remedies Ineffective to Ease Menopausal Symptoms:study 2Health News:Telemedicine Offers New Possibilities in Health Care 2Health News:Olive Oil Emulsions Prevent Cardiac Bypass Surgery 2Health News:Stem Cell Activity Deciphered in the Aging Brain 2Health News:Cardiac Risk is Reduced by Cutting the Sugar in Your Drink 2Health News:Cardiac Risk is Reduced by Cutting the Sugar in Your Drink 3Health News:Echinacea: Cold-Season Cure or Risk? 2
... ORTHOSET Radiopaque Bone Cement ... system: a sterile,ampule containing bone ... pack, and a sterile polyethylene ... a peelable pouch. The interiors ...
Antibiotics (Gentamicin) loaded, high viscosity bone cement for digital use with an average setting time of approx. 6-8 Min., 41.6g of powder and 14.4g of liquid....
... new thinking to address common problems associated ... mm diameter outer arthroscope sheath, the shorter, ... Videoscope has superior access and mobility in ... and especially in the elbow and ankle. ...
... The OMEGA 180 features a wide ... One-Step Small and Variable Pupil Control (U.S. ... pupil sizes down to 1.2mm. Heine's unique ... illumination, making learning BIO easier, and simplifying ...
Medicine Products: